Back to Browse Journals » Drug, Healthcare and Patient Safety » Volume 3

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis

Authors Lewiecki EM

Published 1 December 2011 Volume 2011:3 Pages 79—91


Review by Single-blind

Peer reviewer comments 2

E Michael Lewiecki
New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA

Abstract: Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the principal regulator of osteoclastic bone resorption. Postmenopausal osteoporosis (PMO) is a systemic skeletal disease associated with high levels of RANKL, resulting in a high rate of bone remodeling and an imbalance of bone resorption over bone formation. By inhibiting RANKL in women with PMO, denosumab reduces the rate of bone remodeling, thereby increasing bone mineral density, improving bone strength, and reducing the risk of fractures. In clinical trials of women with osteoporosis and low bone mineral density, denosumab has been well tolerated, with overall rates of adverse events and serious adverse events in women treated with denosumab similar to those receiving placebo. In the largest clinical trial of denosumab for the treatment of women with PMO, there was a significantly greater incidence of cellulitis reported as a serious adverse event, with no difference in the overall incidence of cellulitis, and a significantly lower incidence of the serious adverse event of concussions with denosumab compared with placebo. The evidence supports a favorable balance of benefits versus risks of denosumab for the treatment of PMO. Assessments of the long-term safety of denosumab are ongoing. Denosumab 60 mg subcutaneously every 6 months is an approved treatment for women with PMO who are at high risk for fracture.

Keywords: denosumab, osteoporosis, safety, risk, benefit, FDA

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 


Other articles by this author:

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis

E Michael Lewiecki

Therapeutics and Clinical Risk Management 2009, 5:817-827

Published Date: 14 October 2009

Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect

E Michael Lewiecki

Core Evidence 2009, 4:13-23

Published Date: 18 June 2009

Denosumab: an investigational drug for the management of postmenopausal osteoporosis

E Michael Lewiecki

Biologics: Targets and Therapy 2008, 2:645-653

Published Date: 5 December 2008

Readers of this article also read:

Treatment adherence and other patient-reported outcomes as cost determinants in multiple sclerosis: a review of the literature

Lizán L, Comellas M, Paz S, Poveda JL, Meletiche DM, Polanco C

Patient Preference and Adherence 2014, 8:1653-1664

Published Date: 4 December 2014

Protective effect of picroside II on myocardial ischemia reperfusion injury in rats

Wu N, Li W, Shu W, Jia D

Drug Design, Development and Therapy 2014, 8:545-554

Published Date: 14 May 2014

A review of denosumab for the treatment of osteoporosis

Miyazaki T, Tokimura F, Tanaka S

Patient Preference and Adherence 2014, 8:463-471

Published Date: 8 April 2014

Non-adherence to topical treatments for actinic keratosis

Shergill B, Zokaie S, Carr AJ

Patient Preference and Adherence 2014, 8:35-41

Published Date: 17 December 2013

Novel microfilaricidal activity of nanosilver

Singh SK, Goswami K, Sharma RD, Reddy MVR, Dash D

International Journal of Nanomedicine 2012, 7:1023-1030

Published Date: 22 February 2012

Enhancing the specificity and efficiency of polymerase chain reaction using polyethyleneimine-based derivatives and hybrid nanocomposites

Tong W, Cao X, Wen S, Guo R, Shen M, Wang J, Shi X

International Journal of Nanomedicine 2012, 7:1069-1078

Published Date: 22 February 2012

Antimicrobial and osteogenic effect of Ag-implanted titanium with a nanostructured surface

Zheng Y, Li J, Liu X, Sun J

International Journal of Nanomedicine 2012, 7:875-884

Published Date: 21 February 2012

Surface decoration by Spirulina polysaccharide enhances the cellular uptake and anticancer efficacy of selenium nanoparticles

Yang F, Tang Q, Zhong X, Bai Y, Chen T, Zhang Y, Li Y, Zheng W

International Journal of Nanomedicine 2012, 7:835-844

Published Date: 17 February 2012

Are Toll-like receptor gene polymorphisms associated with prostate cancer?

Kutikhin AG, Yuzhalin AE

Cancer Management and Research 2012, 4:23-29

Published Date: 7 February 2012